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Abstract: In April 2014, the World Health Organization announced the beginning of 
a post-antibiotic era and declared antimicrobial resistance (AMR) a public health 
priority demanding global action. If no action is taken, by 2050 AMR will kill more 
people each year than cancer, with 10 million estimated annual deaths at a cost of 
$100 trillion to the global economy. New therapies to tackle multidrug resistant bac-
terial pathogens are urgently needed. Unlike traditional antibiotics, antivirulence 
drugs inhibit bacterial virulence instead of growth promising to offer a new class of 
superior therapeutics that will be ‘evolution-proof’ and ‘tailored-spectrum’. This 
mini-review discusses the latest emerging evidence on the promised benefits of anti-
virulence drugs over conventional antibiotics, also highlighting the challenges in ev-
aluating these properties for each of the diverse virulence targets that are currently under investigation. 
The author argues that overcoming such challenges early in the development process constitutes an im-
portant step towards successfully progressing each of the expanding number of antivirulence strategies 
into next-generation therapies for common human and animal infections that are becoming increasingly 
refractory to all available antibiotics. 
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1. INTRODUCTION 
 In 2014 the World Health Organization (WHO) declared 
antimicrobial resistance (AMR) a public health priority de-
manding global action. This coincided with WHO’s release 
of an extensive AMR surveillance report that offered the first 
global perspective on the extent of the problem and its 
worldwide impact [1]. The report clearly highlighted very 
high rates of antibiotic resistance across all six WHO regions 
(represented by 114 participating countries) and for most 
bacteria that cause common infections in different settings 
(community, hospitals and the food chain). It became obvi-
ous that for certain pathogens resistance is already wide-
spread and excessively high (> 50% across at least 5 out of 6 
WHO regions), such as resistance to 3rd generation cepha-
losporins among Gram-negative Escherichia coli and Kleb-
siella pneumoniae. Worryingly, co-resistance to fluoroqui-
nolones and aminoglycosides, or even last-resort carbap-
enems and colistin, is frequently encountered in these organ-
isms, leaving health professionals with very few treatment 
options against multi-drug resistant (MDR) strains.  
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 Antibiotic resistance increases the global health and eco-
nomic burden, as patients with drug resistant infections expe-
rience worse clinical outcomes and death more often than 
those infected with drug susceptible bacteria [1]. Currently, 2 
million people are affected each year by antibiotic resistant 
infections in the US alone, resulting in 23,000 deaths, >$20 
billion in health care costs and $35 billion in loss of produc-
tivity [2]. Alarmingly, many common infections that until 
recently were readily treatable, such as urinary tract infec-
tions and foodborne diarrhoea, are becoming resistant to 
most available antibiotics, heralding the beginning of a post-
antibiotic era in which common infections could become 
virtually untreatable and lethal. If no action is taken, AMR is 
predicted to kill more people than cancer by 2050, with 10 
million estimated deaths each year and at a global annual 
cost of up to 100 trillion USD [3]. Clearly, new therapies to 
tackle MDR pathogens are sorely needed.  
 Despite some promising advances in new antibiotic dis-
covery, exemplified by the recent discovery of teixobactin 
[4], the number of new drugs reaching the clinic or currently 
under development is unacceptably small and could not pro-
vide an adequate solution to the pressing AMR problem. 
Importantly, antibiotics work by killing bacteria or inhibiting 
their growth, and this imposes strong pressure for selecting 
resistant variants in the population; whether resistance pre-
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exists or develops as a new mechanism, once it spreads 
among susceptible bacteria it could render expensive new 
drugs ineffective shortly after their introduction to the clinic. 
A new class of drugs designed to disarm (antivirulence) 
rather than kill (antibiotics) bacterial pathogens is promising 
to revitalize the antimicrobial development pipeline and pro-
vide effective therapeutic alternatives to currently failing 
antibiotics with the additional advantages of being evolu-
tionary robust and pathogen-specific. This mini-review pre-
sents the latest research in antivirulence drug development 
with a focus on emerging evidence on their promised bene-
fits over traditional antibiotics and discusses the challenges 
that need to be addressed for their successful development 
into the next-generation antimicrobials. 
2. ANTIVIRULENCE: A ‘DISARM - DON’T KILL’ 
APPROACH 
 The idea of inhibiting virulence as a means of controlling 
bacterial infection has been a central concept driving bacte-
rial pathogenesis research for a long time and before antibi-
otics were discovered [5]. However, the term ‘antivirulence’ 
has not been widely used in this context until the past 10-20 
years, coinciding with a resurgence of research interest in 
antivirulence therapeutics as effective alternatives to antibi-
otics for controlling MDR pathogens. Indeed, the number of 
publications on antivirulence compounds and targets has 
increased noticeably over the past decade (Fig. 1). Early ex-
amples of the antivirulence approach primarily include inac-
tivation of bacterial toxins, such as tetanus, botulinum and 
diphtheria, by neutralizing antitoxin antibodies administered 
to patients post-exposure; an approach that has been success-
fully applied in clinical practice since the early 1900’s [6]. 
Toxins are obvious targets for antivirulence therapies as they 
are exclusively produced by pathogenic species (e.g. Clos-
tridium tetani) or by pathogenic strains of a species (e.g. 
enterohemorrhagic E. coli or EHEC) and are key mediators 
of severe disease pathology [7]. As toxin inactivation during 
infection has been proven to be an effective way to prevent 
or relieve acute disease symptoms, important advances have 
been made in developing new antitoxin monoclonal antibod-
ies, e.g. for Shiga toxin (Urtoxazumab) [8], anthrax [9] and 
C. difficile toxins [10], as well as inhibitors of toxin function 
[11] or expression [12]. In addition to bacterial toxins, many 
other virulence factors have been shown to constitute prom-
ising targets for antivirulence strategies (extensively re-
viewed [13-18]). Some of the most actively researched anti-
virulence strategies include inhibition of bacterial adhesion 
and colonization [19-21], virulence regulation and quorum 
sensing [22-24], and virulence factor folding and secretion 
[25-27]. 
 While antitoxin therapeutics have been utilized in clinical 
practice for decades, drug development for most other viru-
lence targets still remains confined within the realms of aca-
demia or small biotech companies. The obvious lack of in-
terest from large pharmaceuticals to invest in antivirulence 
drug development was to be expected during the golden 
years of antibiotic discovery, yet the landscape has changed 
considerably over the last 10-15 years. Widespread drug 
resistance and the rise of superbugs have turned antibiotics 
from being considered ‘wonder drugs’ to being seen as 
‘worthless drugs’ by big pharma, due to a significant in-
crease in development costs and greatly diminishing profits. 
This vicious circle, where industry profits fed by antibiotic 
overuse and misuse resulted in rendering most antibiotics 
ineffective and subsequently drove large pharma away from 
investing into new antibiotic development due to unfavorable 
development-over-profit cost analyses, is known as the anti-
biotics paradox and is the primary reason for the unaccept-
able drop in new drug numbers [28].  
 While the cost of identifying and developing new antibi-
otics is largely unfavorable to big pharma, the plethora of 
antivirulence targets that have already been validated in vitro 
and in vivo and the availability of effective inhibitors at vari-
ous stages of development should represent excellent oppor-
tunities for big pharma investment. Crucially, there is a 
pressing need for new antimicrobials to replace currently 
failing antibiotics and antivirulence drugs promise to do so in 
a superior way (Fig. 2).   
3. PROMISED BENEFITS OF THE ANTIVIRULENCE 
APPROACH 
3.1. ‘Evolution-proof’ Antimicrobials 
 Antibiotics fail when resistance mechanisms develop and 
spread among bacteria. Resistance to antibiotics develops as 
 
Fig. (1). Number of papers published on ‘antivirulence’ over the last 20 years showing a trend of exponential increase in the last 5 years. 
Documents retrieved from a SCOPUS search using the term: ( TITLE-ABS-KEY ( antivirulence )  OR  TITLE-ABS-KEY ( anti-virulence ) ) 
and conducted on 01/12/2015. A total of 357 documents were retrieved that were published between 1993 and 2015. Of those >90% were 
published in the last decade. N.B: the search term also retrieved papers on antivirulence genes (AVGs), which are inactivated bacterial genes 
that allow new virulence gene expression in certain pathogens, but these represented only 2.5% of the results.  
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a consequence of their mode of action: antibiotics are de-
signed to kill bacteria (bactericidal) or inhibit their growth 
(bacteriostatic), which results in strong selection pressure for 
resistant mutants that can escape killing and propagate in the 
presence of the drug. The antivirulence approach aims to 
inhibit virulence without affecting bacterial growth; an ap-
proach that has the potential to avoid or minimize resistance 
development as selection pressure is anticipated to be weaker 
than in the case of bactericidal or bacteriostatic compounds 
[29]. While this tenet appears to be frequently indicated in 
the literature, for many of the antivirulence compounds cur-
rently under investigation, it has neither been widely evi-
denced nor rigorously tested in the lab or clinic.  
 In fact, the compounds most intensively researched for 
resistance development to date are quorum sensing inhibitors 
(QSI), also known as quorum-quenching (QQ) compounds, 
which do not appear to constitute the most evolutionary ro-
bust antivirulence strategy [30]. Resistance to C-30, one of 
the best characterized QQ compounds, has been shown to 
develop quickly in Pseudomonas aeruginosa lab strains ex-
perimentally and it involved a mechanism of enhanced com-
pound efflux that had not been anticipated [31]. Interest-
ingly, resistance to C-30 was also identified in clinical P. 
aeruginosa isolates not previously exposed to the compound 
and novel resistance mechanisms, other than drug efflux, 
were found to exist naturally [32-33]. While some QSIs 
might not appear to be ‘evolution-proof’, it is important to 
first consider and evaluate the evidence of how strictly they 
fulfill the central ‘disarm-don’t kill’ criterion of the antiviru-
lence approach. This review argues that assessing this crite-
rion in relevant laboratory systems is an important prerequi-
site for all antivirulence compounds (discussed in 4.1 be-
low), including QSIs and other virulence inhibitors for which 
resistance development has already been documented ex-
perimentally [12, 34]. 
 For other antivirulence strategies, however, where inhibi-
tion of a virulence target does not impact on hundreds of 
genes like in the case of quorum sensing [35], or where the 
inhibitor only acts on an extracellular virulence target, resis-
tance might be less likely to develop or develop slower. For 
example, inhibiting iron sequestration in P. aeruginosa by 
gallium-mediated quenching of the pyoverdin siderophore, 
was recently reported to attenuate virulence and growth dur-
ing Galleria mellonella larvae infection and did not select for 
resistance development in vitro unlike conventional antibi-
otic therapy [36]. In addition, only partial resistance was 
observed to the anti-adhesion group 2 capsule polysaccharide 
(G2cps) in E. coli biofilm growth and it involved multiple 
unrelated mutations, suggesting that full resistance develop-
ment is likely to be a rare phenomenon [37]. Similarly, inhi-
bition of the FimH adhesin, an important colonization factor 
of uropathogenic E. coli (UPEC), reduced bladder coloniza-
tion in mice with chronic cystitis and prevented urinary tract 
infection (UTI) by UPEC, including a multidrug resistant 
strain that is currently circulating worldwide [38-39]. FimH 
inhibitors (mannosides) have also been shown to treat cathe-
ter-associated UTI in mice in vivo [40] and prevent Chron’s 
disease E. coli from adhering ex vivo to colonic tissue from 
transgenic mice mimicking CD patients [41]. While resis-
tance development to mannosides remains to be tested, it is 
anticipated that it will be rare given their mode of action: i) 
mannosides are soluble mimics of the FimH adhesin’s natu-
ral ligand on host cells and bind with high affinity to the 
FimH mannose-binding pocket that is invariant in all E. coli 
[42] (mutations in the pocket attenuate virulence and would 
not be under strong selection) and ii) mannosides inactivate 
an extracellular bacterial target, which also makes them less 
susceptible to cross-resistance, i.e. les likely to be rendered 
ineffective by pre-existing resistance mechanisms of MDR 
bacteria (e.g. permeability porin or efflux pump mutations).  
 
Fig. (2). A graphical summary of the promised benefits of the antivirulence approach and the current challenges facing the field in order to 
rigorously evaluate these benefits. Both aspects (benefits and challenges) are highly dependent on the nature of the virulence factor/virulence 
strategy being targeted and this needs to be incorporated into the design of each evaluation assay whether in vitro or in vivo. The challenges 
listed in this figure (and discussed in detail in section 4) are also areas of future antivirulence research that are expected to intensify over the 
coming decades. 
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 The question, however, of whether antivirulence drug 
resistance will spread far and wide is perhaps a more impor-
tant one than whether it will develop in the first place, and 
one for which there is considerable lack of research data. 
Answers to this question are primarily drawn from theoreti-
cal work and predictions based on few experimental evolu-
tion studies to date [29]. Any resistance mechanism to a par-
ticular antivirulence drug could be selected for, against, or 
neither depending on the net benefit the targeted virulence 
factor confers to the pathogen and the pathogen’s population 
structure during treatment [29]. In the case of QSIs environ-
mental conditions are an additional parameter proposed to 
influence the frequency of resistant strains [43].  
 The landscape of resistance evolution and selection is 
clearly more complex for antivirulence drugs than for classic 
antibiotics, where resistance to killing or growth inhibition is 
always beneficial. In order to better predict the fate of anti-
virulence resistance selection and spread in clinically rele-
vant environments, we need more insight into the net bene-
fits conferred by different virulence factors to pathogen fit-
ness and at different environmental niches that are relevant 
to each pathogen’s lifestyle.  
3.2. ‘Tailored-spectrum’ Antimicrobials 
 Inhibiting virulence not only offers a plethora of new 
pharmacological targets urgently needed to revitalize the 
drug development pipeline but can also allow the design of 
therapeutics with uniquely tailored activity spectra. Unlike 
traditional antibiotics, where ‘narrow-spectrum’ usually re-
fers to selective inhibition of either Gram-negative or Gram-
positive bacteria, antivirulence compounds have the potential 
to be species- or even strain-specific, depending on their 
virulence target and how conserved it is between and/or 
within a bacterial species. For example, monoclonal anti-
toxin antibodies can neutralise specific toxins produced by a 
single pathogenic species (e.g. Bacillus anthracis) or by 
pathogenic strains within a species (e.g. Shiga-toxin produc-
ing E. coli or STEC), while inhibitors of sortase A, a con-
served cysteine transpeptidase responsible for anchoring 
surface virulence proteins to the Gram-positive bacterial cell 
wall, can have a broader spectrum of activity against multi-
ple species, e.g. the aryl (β-amino)ethyl ketones are active 
against both staphylococci and bacilli [44]. Similarly, type 
III secretion systems (TTSS) are a common strategy for de-
livering bacterial effectors into host cells that is shared by 
many animal and plant pathogens and TTSS inhibitors have 
been identified that have activity over multiple pathogenic 
species [27]. The best studied include a series of salicylidene 
acylhydrazides with demonstrated activity against Yersinia 
pseudotuberculosis [45], Chlamydia trachomatis [46-47], 
Enteropathogenic E. coli (EPEC) [48], EHEC [49], Salmo-
nella enterica [50-51] and Shigella flexneri [52], while an-
other class of compounds (thiazolidinones) with a broader 
spectrum of inhibition against Gram-negative protein secre-
tion systems (type II and type III) have also been described 
[53]. 
 In addition to species-specificity, and depending on the 
expression profile of the virulence factor being targeted, an-
tivirulence drugs could be designed to have very specific 
activity only at selected host niches during treatment, which 
would likely include the site of infection where expression of 
the targeted virulence factor would be beneficial. This would 
not only preclude undesired inhibition of commensal bacteria 
but also any off-site drug activity that would select for resis-
tant strains at sites of commensal colonization or other natu-
ral reservoirs and environments outside the host.   Inhibition 
of the Staphylococcus aureus golden pigment (staphyloxan-
thin) has been proposed as a good example of narrow-
spectrum environmental specificity that can be achieved by 
antivirulence therapeutics [29]. A cholesterol biosynthesis 
inhibitor also shown to block staphyloxanthin biosynthesis in 
S. aureus [54] would render cells susceptible to killing by 
reactive oxygen species (ROS) only at host sites where the 
presence of S. aureus triggers neutrophil-influx and ROS 
production but not at commensal S. aureus niches. Similarly, 
pilicides and mannosides that respectively target the bio-
genesis or adhesin function of Gram-negative chaperon-
usher fimbriae (also known as pili), such as P and type 1 
fimbriae in E. coli, [55-56] could have the potential to dis-
play environmental specificity in their activity spectrum as 
many of their fimbrial targets are under phase-variable regu-
lation of expression [57]. This ensures that the fimbrial target 
will only be expressed in a fraction of the bacterial popula-
tion at any given time and only under specific environmental 
cues that are often encountered at the host infection site [58]. 
 From the various studies that have evaluated the prom-
ised benefits of different antivirulence drugs to date, it is 
becoming increasingly apparent that outcomes are heavily 
dependent on the nature of the virulence target under investi-
gation. In addition, where evidence is provided that likely 
disproves an anticipated benefit of a particular antivirulence 
approach, research activity immediately intensifies around 
this target-benefit combination, as seen with the develop-
ment of resistance to QSIs for example. While this is provid-
ing invaluable insight and sparked research interest in the 
QSI field, similar research studies are also needed for most 
of the antivirulence targets currently under investigation. 
Given the complexities of the antivirulence approach, there 
are several challenges that need to be addressed when evalu-
ating the benefits of any given antivirulence target and/or 
compound (Fig. 2). These challenges are discussed in the 
section below and should ideally be considered early in the 
development process of an antivirulence strategy.  
4. CHALLENGES IN EVALUATING THE BENEFITS 
OF THE ANTIVIRULENCE APPROACH 
4.1. Antivirulence drug effects on virulence attenuation 
and pathogen fitness and growth  
 The distinct mode of action of antivirulence antimicrobi-
als necessitates a new approach to compound testing that is 
different to antibiotics. Evaluating the central ‘disarm-don’t 
kill’ criterion early upon target selection and using relevant 
assays, needs to be a priority in every proof of concept anti-
virulence target study and for every new compound identi-
fied through high-throughput antivirulence screens for which 
the exact target might not be known. Importantly, the condi-
tions of the in vitro assays to be used for initial evaluation of 
both virulence and growth need to closely reflect the lifestyle 
of the pathogen and mimic the conditions it encounters at the 
various niches it might occupy within and/or outside the 
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host.  The importance of using biologically relevant condi-
tions to test pathogen growth inhibition was nicely demon-
strated for the synthetic furanone QSI C-30. Several studies 
had previously reported virulence attenuation without growth 
inhibition in E. coli, P. aeruginosa and Proteus mirabilis 
using rich complex media [59-61] but in a study assessing P. 
aeruginosa growth in minimal media containing 0.1% 
adenosine (a clinically relevant carbon source requiring func-
tional quorum sensing for utilization) C-30 decreased P. 
aeruginosa growth 5-fold [31]. This was the first study to 
demonstrate that resistance to QSIs could evolve and high-
lighted the importance of testing antivirulence drug effects 
on bacterial growth in physiologically relevant conditions. A 
follow-up study by the same group also demonstrated the 
importance of testing the antivirulence criteria in more than 
one bacterial strain, and preferably in several clinical isolates 
of the species, as C-30 displayed highly variable quorum 
quenching activity and growth inhibition in 50 P. aeruginosa 
isolates from cystic fibrosis patients [33]. The particularities 
of specifically evaluating QSIs have been recently reviewed 
by Defoirdt and colleagues, who proposed a set of best-
practice guidelines for future QSI studies [62]. 
 It is reasonable, thus, to expect that if an antivirulence 
drug inhibits pathogen growth in physiologically relevant 
conditions or in conditions where expression of the virulence 
target is beneficial for the pathogen, treatment with this drug 
will impose strong selection for resistance. Fitness and viru-
lence are two concepts that are often intricately linked for 
pathogens during infection and which also depend on the 
host’s genetics and immune status. This is elegantly dis-
cussed in an opinion article by Allen et al., where the authors 
predict the fate of resistance evolution to antivirulence drugs 
based on the benefit conferred by the virulence factor to be 
targeted [29]. It was argued that resistance could even be 
selected against in situations where an antivirulence drug 
targets ‘locally non-beneficial’ virulence factors, more com-
monly encountered in opportunistic pathogens [29], but this 
remains to be demonstrated. Another area that requires rig-
orous testing is evaluating the net benefits of antivirulence 
drug candidates afforded to different hosts, e.g. with diverse 
genetics for infection susceptibility or immunocompetent 
versus immunocompromised hosts. While it could be argued 
that such data will start to become more widely available as 
more antivirulence drugs enter clinical trials and engage di-
verse patient cohorts, in vivo studies in animals, particularly 
relevant mouse models, can offer a powerful means of gen-
erating this critical insight on antivirulence therapeutic po-
tential at earlier stages of drug evaluation and at a much 
lower cost. Overall, a thorough understanding of the fitness 
costs and benefits associated with expression of different 
virulence factors for each pathogen during infection and in 
different hosts would be hugely insightful in effectively pro-
gressing antivirulence drug development.  
4.2. Evaluating Antivirulence Drug Resistance Develop-
ment and Spread 
 Experimentally testing for resistance development should 
be an integral part of the early stages of antivirulence drug 
development. Resistance to antivirulence antimicrobials is 
defined as the recovery of the virulence phenotype that is 
being inhibited by the drug. If reversal to the virulence phe-
notype is observed either in vitro or in vivo following treat-
ment with a virulence inhibitor, several methods could be 
employed to identify the exact mechanism of resistance. 
Looking for mutations in the actual virulence target gene is 
the obvious starting point but it might not always be suffi-
cient. Unanticipated mutations in the antibiotic efflux pump 
MexAB-OmprM were found to enhance the export of the C-
30 compound from P. aeruginosa cells and mediate resis-
tance to its quorum quenching activity both in vitro and in 
vivo [31]. While spontaneous P. aeruginosa mutants were 
also obtained in this study, the actual resistance mechanism 
was delineated by utilizing a random transposon mutant li-
brary screen [31]. This approach was also used to identify 
the mechanism of partial resistance to the antibiofilm G2cps 
compound in E. coli [37]. Similarly, Hung and colleagues, 
utilized a plasmid mutant library of ToxT, the virulence 
regulator of cholera toxin in Vibrio cholerae and target of the 
antivirulence inhibitor virstatin, to identify virstatin-resistant 
mutants [12]. An alternative approach that offers great power 
for generating invaluable insight into the evolutionary ro-
bustness of antivirulence drugs is to utilize relevant infection 
treatment models (cell- and/or animal-based) in combination 
with whole genome and/or transcriptome sequencing of 
spontaneous mutants or pathogen populations recovered fol-
lowing an antivirulence treatment regime. While global gene 
expression has been used in some cases to explore the full 
antivirulence potential of new compounds, e.g. virstatin and 
TTSS inhibitors [12, 49], future studies should focus on us-
ing this approach to investigate resistance evolution to anti-
virulence drugs.  
 Investigations into the antivirulence resistance mecha-
nisms that develop under in vitro or in vivo conditions can 
not only impart important insight into the probability of re-
sistance developing upon clinical use, but also, most cru-
cially, into whether the mechanism of resistance will have 
the potential to spread among bacteria via horizontal gene 
transfer. It could be argued that resistance spread is a more 
crucial clinical question than resistance development itself. 
This was exemplified by the latest emergence of plasmid-
mediated polymyxin resistance in Gram-negative bacteria 
[63]. Before this very recent report, polymyxin resistance 
was conferred by chromosomal mutations that could not 
spread among bacteria, affording clinicians the use of 
colistin as a last resort therapy for difficult to treat infections 
caused by carbapenem-resistant Enterobacteriaceae (CREs). 
The emergence however of the plasmid-encoded MCR-1 
resistance gene in E. coli isolates of animal and human origin 
in China and the plasmid’s ability to move and be main-
tained by Klebsiella and Pseudomonas is alarming as it her-
alds the loss of another class of last-resort antibiotics [63].   
4.3. Evaluating Antivirulence Selectivity and Off-target 
Effects 
 Evaluating the species- or environmental-specificity (as 
defined in section 3.2) of antivirulence drugs is optimally 
performed when the virulence target is known. However, 
even if the exact target is not known, the spectrum of an in-
hibitor’s antivirulence activity could be evaluated against 
one or multiple pathogens that share the virulence phenotype 
originally used in the high-throughput screen, and then ide-
ally extend into a broader examination of virulence attenua-
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tion in these pathogens. This approach was nicely demon-
strated by Felise and colleagues in a study that identified a 
novel broad-spectrum inhibitor that was active against di-
verse virulence protein secretion systems in different plant 
and animal pathogens [53]. Such studies can also advance 
our understanding of the molecular basis of action of promis-
ing antivirulence compounds and help identify their exact 
virulence targets.  
 In cases where the antivirulence drug target is known 
(e.g. structure-based inhibitor design studies), consideration 
should be given to how conserved the target is across differ-
ent species or within different strains of a species, in order to 
predict compound selectivity and incorporate a tuneable ac-
tivity spectrum into the inhibitor design. For example, the 
sensor kinase QseC mediates virulence gene regulation and 
homologues exist in some important human and plant patho-
gens. However, the small molecule QseC inhibitor LED209 
inhibited QseC signaling in homologues sharing less than 
60% similarity and displayed antivirulence activity across 
EHEC, S. enterica and Francisella tularensis [64] constitut-
ing a promising broad-spectrum inhibitor lead. Other anti-
virulence targets under investigation, such as the virulence 
factor foldase DsbA [65], are even more diverse but can be 
found more widely across bacterial phyla offering exciting 
opportunities for designer-spectrum inhibitor development 
[26]. Interestingly, many important animal and plant patho-
gens have multiple copies of DsbA that are diverse and can 
be involved in specific virulence phenotypes, as for example 
S. enterica with three chromosomal and one plasmid-
encoded DsbA copy [66], and this is something to be taken 
into consideration in future anti-DsbA drug selectivity as-
says.   
 Lastly, the potential of antivirulence drugs to minimize 
off-target effects, in particular harming the host’s resident 
microbiota, is a very attractive property that needs, however, 
to be established in vivo. Microbiome changes in the host 
need to be established during short and long-term antiviru-
lence drug administration using relevant animal infection-
treatment model combinations. In the case of some FDA-
approved compounds with demonstrated antivirulence activ-
ity, such as phosphonosulphonates against S. aureus staphy-
loxanthine [54] and the polycyclic antidepressant maprotiline 
against F. novicida QseC [67], microbiome studies could 
already be performed in human patient cohorts receiving the 
drug for their originally intended purpose. Intriguingly, gut 
microbial profiling studies on healthy vs. patient populations 
show a frequent association between reduction in microbial 
diversity and diseases (dysbiosis), with some studies identi-
fying pathogen communities of low-diversity emerging in 
the gut of critically ill patients [68]. As these patients are 
often in need of antimicrobial interventions, it will be impor-
tant to evaluate the potential of antivirulence antimicrobials 
in eliminating pathogens from the gut or other commensal 
sites before they have the opportunity to cause local or sys-
temic infections.  
CONCLUSION 
 The past 10-20 years have seen a resurgence of research 
interest into the antivirulence approach with many new can-
didate compounds identified and validated in vitro and in 
vivo. The plethora of virulence targets amenable to pharma-
cological inhibition offers exciting prospects for the future of 
antivirulence drug development but also constitutes a major 
challenge in the field. The fate of each antivirulence strategy 
is highly dependent on the virulence factor to be inhibited 
and this will ultimately determine whether any of the devel-
oped inhibitors will successfully deliver the promised bene-
fits of the antivirulence approach. Given the complexities of 
appropriately evaluating each unique antivirulence strategy 
and the critical lack of research data for many of these, it is 
important to not be tempted to draw generalized conclusions 
yet for the fate of all antivirulence compounds currently un-
der investigation. In an era where we have run out of most 
‘off-the-self’ antibiotics and are critically running out of last-
resort options, it is imperative to continue to develop and 
accurately evaluate alternative antimicrobials. With an ever-
expanding list of virulence targets and antivirulence com-
pounds currently under investigation, it is a matter of time 
before antivirulence drugs widely enter clinical practice.  
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